EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

sGC stimulator (BAY 41‐8543) combined with PDE9 inhibitor (BAY 73‐6691) reduces renal fibrosis in 5/6 nephrectomized rats

Xin Chen iD, Denis Delić, Yvonne Liu, Yaochen Cao, Zeyu Zhang, Hongwei Wu, Mohamed M S Gaballa, Thomas Klein, Saban Elitok, Bernhard K Krämer, Berthold Hocher iD

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.14103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Xin Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, German…. Hauptthemen laut MEDLINE: Nephrectomy, Fibrosis, Kidney, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal fibrosis is closely related to the prognosis of chronic kidney disease (CKD). The increase in cGMP reduces renal fibrosis. Soluble guanylate cyclase (sGC) and phosphodiesterase (PDE) are key enzymes that maintain cGMP levels. BAY 41–8543 (1 mg/kg/day) and/or BAY 73–6691 (1 mg/kg/day) were used to treat 5/6 nephrectomized rats for 13 weeks. 5/6 Nephrectomy caused an increase in cystatin C, proteinuria and glomerulosclerosis and renal interstitial fibrosis. Neither sGC stimulation nor PDE9 inhibition alone improved kidney function and morphology, whereas BAY 41–8543 in combination with BAY 73–6691 attenuated renal interstitial fibrosis. This beneficial effect could not be explained by alterations in blood pressure and the renal immune system. BAY 41–8543 in combination with BAY 73–6691 had no effect on renal macrophage, CD4 + T‐cell and CD8 + T‐cell in the late‐stage of 5/6 nephrectomy. RNA sequencing revealed BAY 41–8543 in combination with BAY 73–6691 down‐regulated the expression of fibrosis‐related genes such as Collagen Type I Alpha 1, Collagen Type III Alpha 1 Chain and Collagen Type XIV Alpha 1 Chain. sGC stimulator combined with PDE9 inhibitor attenuated renal fibrosis in 5/6 nephrectomized rats by down‐regulating fibrosis‐related gene expression. This novel approach of using low‐dose combination therapies to minimize side effects while maintaining therapeutic efficacy offers a promising strategy for the treatment of CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NephrectomyFibrosisKidneyRenal Insufficiency, ChronicPyrimidinesAnimalsMaleRatsSoluble Guanylyl CyclaseDisease Models, AnimalRats, Sprague-DawleyDrug Therapy, CombinationPhosphodiesterase InhibitorsPyrazoles

Stichwörter der Autor:innen

5/6 nephrectomychronic kidney diseasephosphodiesterase 9 inhibitorsoluble guanylate cyclase stimulator

Substanzen

PyrimidinesSoluble Guanylyl CyclasepraliciguatPhosphodiesterase InhibitorsPyrazoles

Autor:innen und Institutionen

  • Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Germany.
  • Department of Nephrology, Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.
  • The First Clinical Medical College of Jinan University, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Department of Pathology, Faculty of Veterinary Medicine, Benha University, Toukh, Egypt.
  • Academy of Scientific Research & Technology, Cairo, Egypt.

ORCID-Profile: Xin Chen, Berthold Hocher

Förderung

  • China Scholarship Council

Zitieren

APA

Chen, X., Delić, D., Liu, Y., Cao, Y., Zhang, Z., Wu, H., Gaballa, M. M. S., Klein, T., Elitok, S., Krämer, B. K., & Hocher, B. (2025). sGC stimulator (BAY 41‐8543) combined with PDE9 inhibitor (BAY 73‐6691) reduces renal fibrosis in 5/6 nephrectomized rats. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14103

Vancouver

Chen X, Delić D, Liu Y, Cao Y, Zhang Z, Wu H, et al. sGC stimulator (BAY 41‐8543) combined with PDE9 inhibitor (BAY 73‐6691) reduces renal fibrosis in 5/6 nephrectomized rats. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.14103

BibTeX
@article{Chen2025,
  author = {Chen, Xin and Delić, Denis and Liu, Yvonne and Cao, Yaochen and Zhang, Zeyu and Wu, Hongwei and Gaballa, Mohamed M S and Klein, Thomas and Elitok, Saban and Krämer, Bernhard K and Hocher, Berthold},
  title = {sGC stimulator (BAY 41‐8543) combined with PDE9 inhibitor (BAY 73‐6691) reduces renal fibrosis in 5/6 nephrectomized rats},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.14103}
}
Kostenlos starten →